Growing Through Challenges? – Inari Medical Inc (NARI)

Currently, there are 57.76M common shares owned by the public and among those 49.52M shares have been available to trade.

The company’s stock has a 5-day price change of 6.10% and -27.08% over the past three months. NARI shares are trading -26.09% year to date (YTD), with the 12-month market performance down to -23.17% lower. It has a 12-month low price of $39.90 and touched a high of $71.85 over the same period. NARI has an average intraday trading volume of 994.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.36%, -7.51%, and -18.54% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Inari Medical Inc (NASDAQ: NARI) shares accounts for 85.39% of the company’s 57.76M shares outstanding.

It has a market capitalization of $2.78B and a beta (3y monthly) value of 0.84. The earnings-per-share (ttm) stands at -$0.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.90% over the week and 5.51% over the month.

Analysts forecast that Inari Medical Inc (NARI) will achieve an EPS of -$0.2 for the current quarter, -$0.16 for the next quarter and $0.2 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.39 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.04 a year ago. Earnings per share for the fiscal year are expected to decrease by -1290.16%, and 147.44% over the next financial year.

Looking at the support for the NARI, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on February 29, 2024, with the firm’s price target at $85-$55. Needham coverage for the Inari Medical Inc (NARI) stock in a research note released on January 23, 2024 offered a Buy rating with a price target of $72. Robert W. Baird was of a view on July 19, 2023 that the stock is Outperform, while Jefferies gave the stock Buy rating on October 12, 2022, issuing a price target of $88. Berenberg on their part issued Buy rating on September 29, 2022.

Most Popular

Related Posts